«Health» withdraws two batches of anti-inflammatory and anti-allergic medicine
The Ministry of Health and Community Protection decided to withdraw two batches of a medical product used as anti-inflammatory and anti-allergic, and also required pharmaceutical companies to add warnings to the leaflets of a group of medicines.
In a circular to all health facilities, the Ministry stated that it had withdrawn two batches of the medicinal product (methylprednisolone acetate), which is used as an anti-inflammatory and anti-allergic.
The drawing attributed the manufacturer to the possibility of a slight pink color appearing in these batches, and the pink color may appear at the end of the 60-month shelf life, but other operations that were less than 36 months old were not affected.
The Ministry requested health care practitioners not to use the two affected operations (R12596 and S8908), as they are more than 36 months old from the date of production, and that it is possible for health care practitioners to use the available quantities of the mentioned products for a period of 36 months from the date of production, and care practitioners should not The product was dispensed after 36 months from the date of production, explaining that these drugs are safe to use and have not been withdrawn from the market.
The Ministry also issued another circular, requesting that special warnings and precautions be added to the internal leaflet of the fluoroquinolones taken by mouth, injection and inhalation.
She explained that cases of rupture and aneurysm of the aortic blood vessels, regurgitation and inefficiency of the heart valves, which may cause death, have been reported in patients treated with the fluoroquinolones, and that these products are produced by the European Medicines Agency.
The warnings and special precautions, which the ministry requested to be added, included four warnings: The first is that the data indicate that fluoroquinolones taken by mouth, injection and inhalation may increase the risk of regurgitation and heart valve inefficiency, and the second for patients at risk of developing regurgitation and heart valve inefficiency, must be used These medications are given after careful evaluation of the risks and benefits and after consideration of other treatment options.
The warnings included that conditions that predispose to reflux and heart valve insufficiency include congenital or pre-existing heart valve diseases and connective tissue disorders, such as: Marfan syndrome, Ehlers-Danlos syndrome, Turner syndrome, vasculitis, hypertension, rheumatoid arthritis and endocarditis. The fourth warning: Patients should be informed of the risk of regurgitation and heart valve inefficiency associated with the use of fluoroquinolones, and they are advised to take immediate medical attention if shortness of breath, heart palpitations, or edema of the abdomen or lower extremities develop.
The Ministry confirmed that these medicines have not been withdrawn from the market, and that they are registered in its Drug Administration.
Follow our latest local and sports news, and the latest political and economic developments via Google news